Meet the Experts

Portrait of Jonathan A. Ledermann
Biography Disclosures

Prof. Jonathan A. Ledermann

Go Back

Medical Oncologist

  • UCL Cancer Institute
  • location United Kingdom
Biography Disclosures
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics. 

Programmes developed by Prof. Jonathan A. Ledermann

other Other
Oncology 
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints

Experts
Dr Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr Mark J. O'Connor, Prof. Charlie Gourley, Dr Judith Balmaña, Prof. Sibylle Loibl
  • download Downloadable
    Resources
  • clock MIN
  • calendar Sep 2021
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Oncology 
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy

Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Sep 2021
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from AstraZeneca
e-learning Interactive e-learning
Oncology 
The Role of PARP Inhibition in Clinical Practice

Experts
Prof. Jonathan A. Ledermann, Dr Rebecca Dent, Dr Robert L. Coleman, Prof. Eric Pujade-Lauraine
  • clock 60 MIN
  • calendar Sep 2021
COR2ED EACCME Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Explore all our programmes